Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARP Inhibitor + Bevacizumab Maintenance in HRD Advanced Ovarian, Fallopian-Tube, or Primary Peritoneal Cancer
NCT07472140Phase 3Recruiting
- Sponsor
- N.N. Alexandrov National Cancer Centre of Belarus
- Start
- Jul 2025
- Primary completion
- Jun 2033
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by N.N. Alexandrov National Cancer Centre of Belarus. Started Jul 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07472140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472140.